The Story of Milasen

Starting point and problem

In rare diseases, it can be difficult to narrow down the etiology based solely on patient symptoms. This challenge is particularly pronounced when clinical presentations are complex or when the disease itself is exceedingly rare, often resulting in a significant gap between established diagnostic criteria and the actual clinical status of the patient.

Mila’s case illustrates a process that identified a genetic clue for her condition through whole-genome sequencing, determined whether that clue was linked to an RNA processing defect, and ultimately led to the design of an antisense oligonucleotide (ASO) therapy tailored to her needs.

The key takeaway from this case is not that “reading the genome immediately yields personalized treatment.” Rather, it underscores that genetic information, functional interpretation, drug design, and clinical and regulatory decision-making must be linked in a long, sequential chain.

Research and Therapy Development Workflow

1. Narrowing Down Disease Candidates from Genomic Information

Mila was diagnosed with CLN7-type Batten disease in relation to the MFSD8 gene. The critical issue is not merely identifying the gene name, but confirming the biological relationship between the identified variant and the patient’s disease.

2. Linking DNA Changes to RNA Processing

Some variants may affect processing events such as RNA splicing rather than directly altering the protein sequence. In such cases, it is insufficient to design therapeutic agents based solely on DNA variants; functional data regarding actual RNA processing are required.

3. Intervention via ASOs

Antisense oligonucleotides (ASOs) are short nucleic acid molecules designed to bind to specific RNA sequences. Depending on their target and design, they can be utilized to influence RNA splicing or expression processes.

Milasen is introduced as a patient-specific ASO case developed to target Mila’s particular variant. The term “patient-specific” indicates that the agent is not intended for use across all patients but is designed to address the molecular pathology of an individual patient.

4. Clinical Context: N-of-1 Trials

In the context of therapy development and evaluation for a single patient, this case aligns with discussions surrounding N-of-1 clinical trials. The structure of questions and evidence differs from that of conventional clinical trials, which estimate average effects across populations.

While changes observed in a single patient can constitute important clinical information, they do not justify concluding that the same effect would occur in other patients.

In the 2019 original report, reductions in seizure frequency and duration were observed following treatment, with no serious adverse events reported during the observation period. However, this represents an uncontrolled single-patient observation. Neurological and neuropsychological indicators showed a mixed pattern of stability, decline, and improvement; therefore, the findings do not support claims that the therapy reversed the disease or restored global function.

Key Selections and Obstacles

Success at one step does not automatically guarantee success in the next. Personalized therapy requires a simultaneous balance of speed, robust evidence, safety, ethics, and regulatory compliance.

Key Takeaways from This Case

ASOs Are Not a Drug Class with Fixed Effects

Antisense oligonucleotides (ASOs) may differ in their mechanisms of action and validation methods depending on the target RNA and design objectives. The splicing correction logic demonstrated in the Milasen case should not be generalized to all ASOs.

N-of-1 Trials Imply More Than Just “Small-Scale Clinical Trials”

An N-of-1 trial refers to a therapeutic question and evidence design tailored to an individual patient. When evaluating efficacy, it is essential to consider the limitations inherent in natural history baselines, observational endpoints, pre- and post-treatment comparisons, and the absence of control conditions.

Genomic Analysis May Be the Starting Point for Therapy, But It Is Not a Sufficient Condition

Even when genomic information narrows down candidate genes, functional analysis and clinical judgment must follow. Multiple independent verification steps are required to link analytical findings to therapeutic agents.

Interpretations at the Time and Contemporary Reassessment

The current rewrite centers on the primary case report published in the New England Journal of Medicine (NEJM) to outline the patient-specific antisense oligonucleotide (ASO) development pathway, while clearly delineating the following boundaries:

• The outcomes of this single case are not generalized as efficacy data for broader patient populations.
• The Milasen case is not characterized as representing typical regulatory approval processes or standard-of-care treatments.
• The general principles of ASOs are explained separately from the design logic applied specifically to Mila.
• Observed findings are described solely in terms of their association with treatment, without confirming causal efficacy.
• FDA documents pertaining to individualized ASO development address exploratory research and do not imply standard regulatory approval for Milasen.

What This Explanation Does Not Address

• Diagnostic or therapeutic recommendations based on individual genetic information
• The assertion that Milasen can be applied to other patients
• Generalizations representing all mechanisms of action and clinical trial outcomes of antisense oligonucleotides (ASOs)
• Definitive claims regarding the current regulatory approval status

Connection Concept / Narrative

• Concept: antisense oligonucleotides, RNA splicing, personalized therapy, N-of-1
• Concept linkages: genotype–phenotype correlations, variant interpretation
• Narrative linkages: rare disease diagnosis, precision medicine initiatives

References

• Kim et al., Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease (NEJM 2019)
• FDA 2021 individualized ASO draft guidance
• FDA 2026 individualized therapies draft guidance
• Patient-customized N-of-1 ASO context